What Adamed Group does

Adamed Group (legally Adamed Pharma S.A.) is a family-owned Polish pharmaceutical-biotechnology company founded in 1986 that develops, manufactures, and distributes a broad pharmaceutical portfolio across 19 therapeutic areas. Its offerings span prescription drugs (Leki na receptę), over-the-counter medications (Leki bez recepty), dietary supplements (Suplementy diety), dermocosmetics (Dermokosmetyki), and medical devices (Wyroby medyczne), underpinned by approximately 300 molecules in portfolio and 277 pharmacy patents. Core technology is centered on two R&D tracks: original drug development (Rozwój leków oryginalnych) and added-value drug formulation (Rozwój leków z wartością dodaną), both rooted in Polish scientific research and proprietary patents. Manufacturing scale is significant, with 103 million unit packages produced in 2025.

The company's go-to-market is a multi-country enterprise channel model rather than direct-to-consumer. Distribution runs through pharmacies and healthcare providers across prescription and OTC channels, executed via 8 international representative offices in Poland, Spain, Italy, Czech Republic, Slovakia, Ukraine, Kazakhstan, Uzbekistan, and Vietnam, with products available in several dozen additional countries. End customers are patients and healthcare professionals; pricing is not publicly disclosed and operates through standard pharmaceutical pharmacy-channel mechanics. Supporting sub-brands — Adamed Discovery (R&D platform), Adamed Expert (HCP information portal), Adamed Safety Portal (adverse-event reporting), and Fundacja Adamed plus programs such as Adamed SmartUP and Adamed dla Seniora — extend the company beyond pure product sales into R&D transparency, medical education, and CSR engagement.

Ownership is concentrated in the Adamkiewicz family across three generations: founder Marian Adamkiewicz, Supervisory Board Chair and co-owner Małgorzata Adamkiewicz, and third-generation Business Development Director Karolina Adamkiewicz. Leadership has publicly signaled intent to reposition the company from cost-based competition toward innovation-driven global expansion, with explicit M&A interest in CEE and a stated ambition to become a European champion. Recent activity includes a Bloomberg Future of Finance in CEE Forum appearance by Karolina Adamkiewicz discussing CEE M&A in May 2026 and Małgorzata Adamkiewicz signing the "Polska Przedsiębiorcza" Roadmap in June 2026, indicating active corporate-level positioning in policy and capital-markets dialogue.

Name

Adamed Group

Legal name

Adamed Pharma S.A.

Website

https://adamed.com.pl

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Adamed Pharma S.A. is a family-owned Polish pharmaceutical-biotechnology company that develops, manufactures, and distributes prescription drugs, OTC medications, dietary supplements, dermocosmetics, and medical devices across 19 therapeutic areas, serving patients and healthcare professionals in dozens of countries via 8 international representative offices.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Pharmaceutical products
• Prescription drugs
• Over-the-counter medicines
• Dietary supplements
• Medical devices

Headquarters

HQ city

Czosnow

HQ country

Poland

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Sale of prescription drugs, OTC medications, dietary supplements, dermocosmetics, and medical devices across 19 therapeutic areas. Products are distributed through pharmacies and healthcare providers in dozens of countries globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Adamed Group develops, manufactures, and distributes a portfolio of pharmaceutical products including prescription drugs, over-the-counter (OTC) medicines, dietary supplements, dermocosmetics, and medical devices across approximately 19 therapeutic areas. The company operates an end-to-end pharmaceutical business built on original drug research and added-value drug development, with products distributed through pharmacies and healthcare providers in dozens of countries worldwide.

Product overview

Adamed Group is a Polish pharmaceutical-biotechnological company with 40 years of experience, operating as a unified portfolio of prescription drugs (Leki na receptę), over-the-counter medicines (Leki bez recepty), dietary supplements (Suplementy diety), dermocosmetics (Dermokosmetyki), and medical devices (Wyroby medyczne). The company maintains approximately 300 molecules across 19 therapeutic areas with 277 patents. Supporting sub-brands include Adamed Discovery (original drug R&D platform), Adamed Expert (professional information portal), and Fundacja Adamed (corporate foundation). Social programs such as ADAMED SmartUP (educational), Adamed dla Seniora (senior health), Głęboki oddech (respiratory health), Odnaleźć siebie (mental health), and Serce na nowo (cardiovascular health) complement the product ecosystem. The company also operates a drug safety portal for adverse reaction reporting.

Differentiator

Problem solved

Functional benefit

Brands

• Adamed Discovery: Platform showcasing original drug development
• Adamed Expert
• ADAMED SmartUP
• Fundacja Adamed
• Adamed Expert Fundacja

Products and services

• Leki na receptę (Prescription Drugs) Prescription pharmaceutical products addressing chronic civilization diseases across multiple therapeutic areas; sold through pharmacies and healthcare providers in markets where Adamed holds regulatory approval.
• Leki bez recepty (OTC Drugs) Over-the-counter pharmaceutical products available without prescription for common health conditions; distributed through pharmacy networks across the markets where Adamed operates.
• Suplementy diety (Dietary Supplements) Nutritional supplements designed to complement diet and support overall health; sold alongside the company's pharmaceutical portfolio through pharmacy and retail channels.
• Dermokosmetyki (Dermocosmetics) Skincare and cosmetic products with therapeutic properties intended for dermatological care; distributed as part of Adamed's broader consumer health portfolio.
• Wyroby medyczne (Medical Devices) Medical devices intended for patient diagnosis, monitoring, or treatment purposes; sold through pharmacy and healthcare channels.
• Adamed Safety Portal Online portal for reporting adverse drug reactions and accessing educational materials on drug safety; provided to patients, healthcare professionals, and regulatory stakeholders.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ADAMED-Sp-z-oo-248929018482154
• LinkedInlinkedin.com/company/45810

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adamed Group